Findings from clinical studies (N=63) through eight years of long-term follow-up (n=3) continue to support ZYNTEGLO as a potentially curative one-time gene therapy for patients with beta-thalassemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results